Great Lakes Advisors LLC Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Great Lakes Advisors LLC decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 44,245 shares of the medical equipment provider’s stock after selling 5,714 shares during the period. Great Lakes Advisors LLC’s holdings in Lantheus were worth $3,958,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the 4th quarter worth approximately $27,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares during the last quarter. World Investment Advisors LLC purchased a new stake in shares of Lantheus in the 3rd quarter worth approximately $60,000. Finally, RiverPark Advisors LLC purchased a new stake in shares of Lantheus in the 3rd quarter worth approximately $74,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Lantheus Trading Up 1.8 %

Shares of LNTH opened at $101.10 on Friday. The business’s fifty day simple moving average is $91.87 and its two-hundred day simple moving average is $96.90. Lantheus Holdings, Inc. has a 12 month low of $56.44 and a 12 month high of $126.89. The company has a market cap of $6.92 billion, a price-to-earnings ratio of 16.82 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent research reports. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial upped their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.